Blisters, Skin Pain, and Mucosal Erosions After a New Medicine

An adult develops fever, malaise, painful eyes, oral erosions, and rapidly spreading dusky macules with flaccid blisters ten days after starting lamotrigine while also taking several long standing medicines. The skin hurts more than it itches, gentle pressure causes epidermal separation, and genital mucosa is involved. The pattern is a severe cutaneous adverse reaction until proven otherwise, with immediate threats to airway, ocular surfaces, fluid balance, infection risk, and internal organs.

Case focus#

The central decision is whether this is Stevens-Johnson syndrome or toxic epidermal necrolysis requiring immediate withdrawal of likely culprit medicines and transfer to an experienced unit, rather than a benign exanthem treated by continuing exposure. Extent of detached or detachable epidermis, mucosal involvement, systemic physiology, and disease progression guide classification and level of care, but action should not wait for perfect body surface calculation or biopsy.

This analysis concentrates on the opening phase: building a usable problem representation, recognizing time-sensitive threats, and choosing the safest next action before diagnostic certainty is available.

Problem representation#

The useful representation is not a label alone. It combines the tempo of the problem, the setting, the physiologic or functional threat, the evidence already available, and the important information that is still missing. For this severe cutaneous adverse reaction analysis, the working frame must remain broad enough to compare Stevens-Johnson syndrome or toxic epidermal necrolysis, Drug reaction with eosinophilia and systemic symptoms, Acute generalized exanthematous pustulosis, Staphylococcal scalded skin syndrome without allowing a familiar first impression to become an untested conclusion.

The setting materially changes the plan: An emergency department with immediate burn or intensive care support, dermatology, ophthalmology, airway expertise, biopsy, and monitored fluid management.. Available monitoring, access to consultation, travel time, record continuity, and the reliability of follow-through alter what counts as a safe next step. A plan that is reasonable in a continuously monitored environment may be unsafe when results return after discharge or urgent reassessment is difficult.

Immediate safety priorities#

• Airway mucosal injury: Hoarseness, stridor, dyspnea, heavy secretions, hypoxemia, or progressive oral and pharyngeal erosions require immediate airway assessment.
• Ocular surface involvement: Eye pain, photophobia, conjunctival injection, discharge, or epithelial defect can produce permanent vision loss without early ophthalmic care.
• Rapid epidermal detachment: Expanding tenderness, duskiness, blistering, or positive epidermal separation signals progression and increases fluid, temperature, and infection risk.
• Systemic organ dysfunction: Hypotension, oliguria, altered mentation, rising urea, acidosis, hypoxemia, or cytopenias increase severity and influence prognostic assessment.

These findings are action signals rather than diagnostic shortcuts. They determine the pace of stabilization, consultation, and escalation while the causal analysis continues in parallel.

Prioritized differential diagnosis#

Stevens-Johnson syndrome or toxic epidermal necrolysis#

What supports it. Skin pain, dusky targetoid macules, epidermal detachment, multiple mucosal erosions, fever, and a plausible new medicine strongly support epidermal necrolysis.

What argues against it or keeps uncertainty open. A purely pruritic morbilliform eruption without skin pain, duskiness, blisters, or mucosal injury is less consistent.

Discriminating next step. Stop likely culprit medicines immediately, document detached and detachable body surface area, obtain biopsy, and transfer to experienced supportive care.

Drug reaction with eosinophilia and systemic symptoms#

What supports it. Longer latency, facial edema, widespread eruption, eosinophilia, lymphadenopathy, and hepatitis or nephritis support DRESS.

What argues against it or keeps uncertainty open. Prominent epidermal detachment and severe mucosal erosions favor SJS or TEN, though overlap and organ involvement require careful review.

Discriminating next step. Check blood count, liver and kidney injury, fever chronology, culprit timing, and biopsy while stopping implicated drugs.

Acute generalized exanthematous pustulosis#

What supports it. Abrupt fever with many small sterile nonfollicular pustules, neutrophilia, and short drug latency supports AGEP.

What argues against it or keeps uncertainty open. Dusky painful skin, flaccid blisters, and extensive mucosal erosion are less typical.

Discriminating next step. Use morphology, drug timing, blood count, cultures when indicated, and histopathology to distinguish the eruption.

Staphylococcal scalded skin syndrome#

What supports it. Superficial tender desquamation, systemic illness, and a staphylococcal source, especially in children or kidney impairment, can mimic epidermal necrolysis.

What argues against it or keeps uncertainty open. Mucous membranes are usually spared and histology shows a different cleavage level.

Discriminating next step. Obtain biopsy at the correct edge and targeted cultures while treating systemic infection when suspected.

Autoimmune blistering disease#

What supports it. Pemphigus or pemphigoid can cause mucosal erosions and blisters, often with a more subacute course.

What argues against it or keeps uncertainty open. Acute febrile onset after a high risk medicine with dusky necrotic lesions favors SJS or TEN.

Discriminating next step. Use lesional histology and perilesional direct immunofluorescence when an autoimmune blistering process remains possible.

The differential is ranked but not closed. Probability, consequence of delay, reversibility, and test burden are considered together. A dangerous alternative can deserve early exclusion even when it is not the statistically most likely explanation.

Evidence-gathering strategy#

• Immediate airway, eye, and hemodynamic assessment. Mucosal injury, barrier loss, and systemic inflammation can threaten breathing, vision, perfusion, and temperature control within hours. Interpretation: Any compromise accelerates airway action, ophthalmic treatment, critical care, and transfer before diagnostic completion.
• Complete skin and mucosal map. Painful duskiness, blisters, detachable skin, and oral, ocular, genital, and airway sites define extent and progression. Interpretation: Detached plus detachable body surface area helps classify SJS, overlap, or TEN and informs supportive needs.
• Dated medicine exposure table. Start, stop, dose increase, intermittent use, prior tolerance, and known latency are essential for causal attribution. Interpretation: A high risk drug started within a compatible window ranks above medicines taken unchanged for years, though formal causality review remains necessary.
• Skin biopsy and differential studies. Routine histology can confirm full thickness epidermal necrosis and distinguish other blistering or infectious disorders. Interpretation: Biopsy supports classification but must not delay stopping culprit exposure or supportive treatment.
• Severity and organ monitoring. Blood count, electrolytes, glucose, bicarbonate, urea, creatinine, liver tests, oxygenation, urine output, and infection signs identify complications and inform SCORTEN. Interpretation: Trend based severity supports level of care and prognosis; fever alone does not prove secondary infection.

Tests are selected because they can change a decision, not because a broad panel feels comprehensive. Results are interpreted with their timing, pretest probability, measurement limitations, recent treatment, and the possibility that an apparently reassuring value was obtained too early or under the wrong conditions.

Progressive course and interpretation#

All nonessential recent medicines are stopped and a dated exposure table is constructed. The airway remains patent, but oral pain limits intake and eye examination shows early epithelial injury. Dermatology obtains a biopsy while ophthalmology begins surface protection. Detachable epidermis expands from 6 to 15 percent of body surface over hours, shifting classification from SJS toward overlap disease and strengthening the need for intensive supportive care. A structured culprit assessment makes lamotrigine far more plausible than stable medicines taken for years.

The trajectory is evidence. Improvement after an intervention may support a mechanism without proving it, while nonresponse should prompt a check of the diagnosis, delivery of the intervention, timing, adherence, and competing pathology. Discordant data should be explained rather than averaged away.

Management reasoning#

• Stop likely culprit medicines now. Continued exposure can worsen epidermal necrolysis, so probable recent triggers and nonessential agents are withdrawn before perfect certainty.
• Transfer to experienced supportive care. Temperature, fluid, nutrition, pain, wound, airway, and infection care require coordinated burn or intensive care methods adapted to SJS and TEN.
• Protect eyes and mucosa early. Urgent ophthalmic examination and repeated ocular, oral, genital, and urinary care reduce scarring and functional loss.
• Use conservative wound handling. Nonadherent dressings, careful handling, pressure prevention, and avoidance of unnecessary debridement protect viable tissue and reduce pain.
• Individualize systemic therapy. Corticosteroids, cyclosporine, intravenous immunoglobulin, or other immune treatment varies by timing, severity, contraindications, and local evidence and should not displace supportive care.

Management remains proportional to severity and uncertainty. It includes explicit monitoring targets, foreseeable adverse effects, and stop or escalation conditions. Exact drug selection, dosing, and procedure details depend on verified individual factors, current local protocols, contraindications, and the responsible treating team; the analytical value here is the decision structure and its guardrails.

Communication and shared decisions#

Tell the person and family that this is a medical emergency caused by loss of the skin and mucosal barrier, not a routine allergy rash. Explain which medicines are stopped now, which remain uncertain, why early eye and airway evaluation matter, and why long term records must name the culprit precisely. Avoid labeling every drug ever taken as an allergy because inaccurate lists can later block needed treatment.

The communication task includes what is known, what remains uncertain, why the next step is recommended, what alternatives exist, and which change should trigger urgent reassessment. Teach-back, qualified interpretation when needed, accessible formats, and a named owner for pending results turn information into a safer plan.

Continuity and safety net#

• Escalate immediately for hoarseness, breathing difficulty, eye pain, reduced vision, rapidly expanding skin pain, hypotension, or reduced urine output.
• Record the most likely culprit, exposure dates, reaction phenotype, and medicines specifically evaluated as less likely in every relevant health record.
• Arrange long term ophthalmic, oral, genital, pulmonary, skin, and psychological follow-up because sequelae can appear after reepithelialization.
• Provide a clear written avoidance plan and medication alternatives before discharge, with a route to correct future inaccurate allergy entries.

Follow-through is verified, not assumed. The record should identify who receives each pending result, the time window for reassessment, the contingency if contact fails, and the clinical or functional outcome that will show whether the plan is working.

Equity and systems analysis#

Skin erythema may be harder to recognize on darker skin, so rely on pain, duskiness, mucosal injury, blistering, and palpation rather than redness alone. Qualified interpretation and accessible consent are necessary during rapid transfer. Medication histories may be fragmented across pharmacies or countries; use bottles, dispensing records, and family information without delaying cessation of likely culprits.

Access conditions belong in the causal model. Transportation, medication cost, work schedules, caregiving, health literacy, language, disability access, digital connectivity, and prior experiences of care can alter both the observed presentation and the feasibility of the plan. Addressing those constraints improves diagnostic validity as well as fairness.

Reasoning capabilities demonstrated#

• Recognizes skin pain and mucosal erosion as early danger signs of epidermal necrolysis.
• Uses body surface progression and organ physiology to determine level of care.
• Ranks drug causality from exact latency, dose change, and prior tolerance.
• Protects ocular and airway function before histopathologic confirmation returns.
• Documents a precise long term drug avoidance record without indiscriminate allergy labeling.

Key takeaways#

• A painful blistering eruption with mucosal erosion after a new medicine is an emergency requiring immediate drug cessation.
• Early ophthalmology, airway assessment, fluid and temperature support, and gentle wound care are central treatments.
• Culprit attribution depends on a dated exposure history and structured causality, not simply the longest medication list.